Is Gilead Sciences Too Dependent On These 2 Areas of Its Business?

Is Gilead Sciences Too Dependent On These 2 Areas of Its Business?

Source: 
Motley Fool
snippet: 
  • The biopharmaceutical company's largest segment, which focuses on HIV drugs, generates the bulk of revenue.
  • COVID-19 drug, Veklury, is another top-selling product, but its sales may soon fade.
  • Excluding these two business areas leaves Gilead with just one-fifth of its revenue.